Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Glioblastoma 393Brain Neoplasms 162Glioma 156Gliosarcoma 130Astrocytoma 111Central Nervous System Neoplasms 109Melanoma 75Oligodendroglioma 73Neuroblastoma 44Neoplasms 33Medulloblastoma 33Neoplasm Metastasis 29Recurrence 28Ependymoma 25Sarcoma 23Sarcoma, Ewing 22Rhabdomyosarcoma 18Small Cell Lung Carcinoma 16Lymphoma 16Carcinoma, Non-Small-Cell Lung 16Diffuse Intrinsic Pontine Glioma 15Lung Neoplasms 14Breast Neoplasms 14Ovarian Neoplasms 13Neuroendocrine Tumors 13Choroid Plexus Neoplasms 13Optic Nerve Glioma 11Neuroectodermal Tumors, Primitive 11Spinal Cord Neoplasms 10Rhabdoid Tumor 10

Interventions

pembrolizumab 1Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Melanoma × Temozolomide × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡